close up illustration of WATCHMAN in the LAA

Get Informed About the WATCHMANTM Implant Procedure

Learn more about the new TruSealTM Access System
98.5% Implant success rate in the EWOLUTION Prospective Registry

How does the WATCHMAN work?

  • The WATCHMAN implant procedure does not require open-heart surgery and is typically performed under general anaesthesia or conscious sedation.
  • The WATCHMAN procedure usually lasts about an hour and consists of a small incision performed through the groin allowing the insertion of a catheter into the femoral vein which will guide the WATCHMAN device into the heart. Due to this small incision, the patients often recover faster and have less pain than after an open surgery. They are generally discharged after one day.
  • A transesophageal echocardiogram (TEE) is usually performed to measure the left atrial appendage (LAA) to determine the size of the WATCHMAN Device to be implanted.
  • After the interatrial septum is crossed using a standard transseptal access system, the WATCHMAN Access Sheath is advanced over a guidewire into the left atrium. The Access Sheath is then advanced into the distal portion of the LAA over a pigtail catheter.
  • The WATCHMAN Delivery System is prepped, inserted into the Access Sheath, and slowly advanced under fluoroscopic guidance. WATCHMAN is then deployed into the LAA. The device release criteria are confirmed via fluoroscopy and TEE prior to its release.
Learn more about the design features of WATCHMAN & TruSeal Access System

What is the recommended post-implant regime for my patient?

Post-implant medication is at the discretion of each physician and is subject to the patient's specific condition and medical history. Boston Scientific does provide general guidelines in the instructions for use (IFU) of the device. These have been updated based on the robust clinical results observed in the EWOLUTION registry. With the new recommendations, patients for whom there is no specific medical need for continued use of aspirin could be taken of the drug after a minimum period of 12 months. In addition, depending on patient preference, risk of bleeding and stroke risk, clopidogrel and/or any NOAC or OAC should be prescribed for at least 3 months following the procedure. For additional information, please contact your implanting centre. 

Referring a Patient

Thinking about referring one of your NVAF patients? Here's what you need to know.

Who is WATCHMAN for?

See which of your NVAF patients could benefit from WATCHMAN

Selecting Appropriate Patients

Reference:
* Implant success defined as deployment and release of the device into the LAA; no leak ≥ 5 mm 
1. Boersma LVA et al. Implant Success and Safety of Left device: periprocedural outcomes from the EWOLUTION Registry. Eur Heart J 2016;37(31):2465-74. 
2. INTERIM POST-MARKET SURVEILLANCE STUDY REPORT on EWOLUTION May 5, 2017 

CAUTION: The law restricts these devices to sale by our on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Information for the use only in countries with applicable health authority product registrations. Information contained herein is for distribution outside the U.S., Japan and France.